Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc-Matthieu Fornecker

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Hemasphere|June 7, 2023
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort StudyIrene Defrancesco, Virginia Valeria Ferretti, Pierre Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Haematologica|December 30, 2021
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort studyAmira Marouf, Anne Segolene Cottereau, Salim Kanoun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA StudyGuillaume Cartron, Emmanuel Bachy, Hervé Tilly, et al.
Haematologica|May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND studyGabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohortAmélie Anota, Mathurine Basset, Emilie Charton, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Hemasphere|June 7, 2023
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort StudyIrene Defrancesco, Virginia Valeria Ferretti, Pierre Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Haematologica|December 30, 2021
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort studyAmira Marouf, Anne Segolene Cottereau, Salim Kanoun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA StudyGuillaume Cartron, Emmanuel Bachy, Hervé Tilly, et al.
Haematologica|May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND studyGabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohortAmélie Anota, Mathurine Basset, Emilie Charton, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Pageof 8